Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2015

01.05.2015 | Clinical trial

Lymph node status in inflammatory breast cancer

verfasst von: Julie S. Wecsler, Welela Tereffe, Rose C. Pedersen, Michelle R. Sieffert, Wendy J. Mack, Haiyan Cui, Christy A. Russell, Ryan R. Woods, Rebecca K. Viscusi, Stephen F. Sener, Julie E. Lang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Positive lymph node status in breast cancer is known to be an adverse prognostic factor, but the effect of lymph node (LN) status in inflammatory breast cancer (IBC) has not been evaluated. This study was designed to investigate the association between lymph node status and overall survival (OS) in individuals with IBC. Using the Surveillance, Epidemiology, and End Results (SEER) 18 registry, we collected data on 761 patients diagnosed with non-metastatic IBC from 2004 to 2008. Survival analysis was performed using the Kaplan–Meier method. Cox proportional hazard regression was performed to evaluate univariate and multivariate associations between estrogen and progesterone receptor (ER/PR) status, treatment, and OS. Positive nodal status was associated with a significant decrease in OS (p < 0.001). Five-year survival for LN-positive and LN-negative patients was 49 and 66 %, respectively. In node-positive patients, ER or PR positivity was associated with improved OS, (p = 0.025, p = 0.007). In node-positive patients, the combination of surgery and radiation therapy improved OS when compared with surgery alone (p = 0.002). Nearly 80 % of the patients in this study had nodal metastasis. Positive nodal status was found to be an adverse prognostic factor. ER/PR positivity and treatment with surgery and radiation in node-positive patients was found to improve outcomes. Further studies are required to characterize the biology of IBC and guide the optimal treatment of this disease.
Literatur
1.
Zurück zum Zitat Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826. doi:10.1002/cncr.25682 CrossRefPubMed Dawood S, Ueno NT, Valero V et al (2011) Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer 117(9):1819–1826. doi:10.​1002/​cncr.​25682 CrossRefPubMed
3.
Zurück zum Zitat Hance KW, Anderson WF, Devesa SS et al (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975. doi:10.1093/dji172 CrossRefPubMedCentralPubMed Hance KW, Anderson WF, Devesa SS et al (2005) Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 97(13):966–975. doi:10.​1093/​dji172 CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Zell JA, Tsang WY, Taylor TH et al (2009) Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 11(1):R9. doi:10.1186/bcr2225 CrossRefPubMedCentralPubMed Zell JA, Tsang WY, Taylor TH et al (2009) Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 11(1):R9. doi:10.​1186/​bcr2225 CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Ueno NT, Buzdar AU, Singletary SE et al (1997) Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemoth Pharm 40(4):321–329. doi:10.1007/s002800050664 CrossRef Ueno NT, Buzdar AU, Singletary SE et al (1997) Combined-modality treatment of inflammatory breast carcinoma: Twenty years of experience at M.D. Anderson Cancer Center. Cancer Chemoth Pharm 40(4):321–329. doi:10.​1007/​s002800050664 CrossRef
12.
Zurück zum Zitat Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al (2004) Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 4(6):415–419CrossRefPubMed Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU et al (2004) Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer 4(6):415–419CrossRefPubMed
13.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program ( http://www.seer.cancer.gov ) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973–2009) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission Surveillance, Epidemiology, and End Results (SEER) Program ( http://​www.​seer.​cancer.​gov ) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973–2009) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969–2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission
14.
Zurück zum Zitat Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493PubMed Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15(7):2483–2493PubMed
17.
Zurück zum Zitat Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460–469PubMed Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17(2):460–469PubMed
18.
Zurück zum Zitat Abe O, Abe R, Enomoto K et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106. doi:10.1016/S0140-6736(05)67887-7 CrossRef Abe O, Abe R, Enomoto K et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106. doi:10.​1016/​S0140-6736(05)67887-7 CrossRef
19.
Zurück zum Zitat EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135. doi:10.1016/s0140-6736(14)60488-8 CrossRef EBCTCG (Early Breast Cancer Trialists’ Collaborative Group) (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135. doi:10.​1016/​s0140-6736(14)60488-8 CrossRef
21.
Zurück zum Zitat Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.1016/s0140-6736(11)60993-8 CrossRefPubMed Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.​1016/​s0140-6736(11)60993-8 CrossRefPubMed
22.
Zurück zum Zitat Stearns V, Ewing CA, Slack R et al (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235–242. doi:10.1245/aso.2002.9.3.235 CrossRefPubMed Stearns V, Ewing CA, Slack R et al (2002) Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9(3):235–242. doi:10.​1245/​aso.​2002.​9.​3.​235 CrossRefPubMed
23.
Zurück zum Zitat Cristofanilli M, Valero V, Buzdar AU et al (2007) Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436–1444. doi:10.1002/cncr.22927 CrossRefPubMed Cristofanilli M, Valero V, Buzdar AU et al (2007) Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer 110(7):1436–1444. doi:10.​1002/​cncr.​22927 CrossRefPubMed
25.
Zurück zum Zitat Dawood S, Cristofanilli M (2011) Inflammatory breast cancer: what progress have we made? Oncol NY 25(3):264–273 Dawood S, Cristofanilli M (2011) Inflammatory breast cancer: what progress have we made? Oncol NY 25(3):264–273
26.
Zurück zum Zitat Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377–384. doi:10.1016/S0140-6736(09)61964-4 CrossRefPubMed Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375(9712):377–384. doi:10.​1016/​S0140-6736(09)61964-4 CrossRefPubMed
Metadaten
Titel
Lymph node status in inflammatory breast cancer
verfasst von
Julie S. Wecsler
Welela Tereffe
Rose C. Pedersen
Michelle R. Sieffert
Wendy J. Mack
Haiyan Cui
Christy A. Russell
Ryan R. Woods
Rebecca K. Viscusi
Stephen F. Sener
Julie E. Lang
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2015
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3367-6

Weitere Artikel der Ausgabe 1/2015

Breast Cancer Research and Treatment 1/2015 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.